Ptc Therapeutics, Inc S-3ASR, filed Jun 19, 2020
Ptc Therapeutics, Inc. (PTCT)
S-3ASR
2020-06-19
View Original
Added on
October 15, 2026
As filed with the Securities and Exchange Commission on June 19, 2020
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-3
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
UNDER
THE SECURITIES ACT OF 1933
PTC THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
| |
Delaware
|
| |
04-3416587
|
|
| |
(State or other jurisdiction of
incorporation or organization) |
| |
(I.R.S. Employer
Identification Number) |
|
100 Corporate Court
South Plainfield, NJ 07080
(908) 222-7000
South Plainfield, NJ 07080
(908) 222-7000
(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant’s Principal Executive Offices)
Stuart W. Peltz, Ph.D.
Chief Executive Officer
PTC Therapeutics, Inc.
100 Corporate Court
South Plainfield, New Jersey 07080
(908) 222-7000
Chief Executive Officer
PTC Therapeutics, Inc.
100 Corporate Court
South Plainfield, New Jersey 07080
(908) 222-7000
(Name, Address, Including Zip Code, and Telephone Number, Including Area Code, of Agent for Service)
| |
Copies to:
|
| |||
| |
Richard Aldridge
Morgan, Lewis & Bockius LLP 1701 Market Street Philadelphia, Pennsylvania 19103 Telephone: (215) 963-5000 Fax: (215) 963-5001 |
| |
Mark E. Boulding
Executive Vice President and Chief Legal Officer PTC Therapeutics, Inc. 100 Corporate Court South Plainfield, New Jersey 07080-2449 Telephone: (908) 222-7000 Fax: (908) 222-1128 |
|
Approximate date of commencement of proposed sale to the public: From time to time after this registration statement becomes effective.
If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box. ☐
If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box. ☒
If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐
If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐
If this Form is a registration statement pursuant to General Instruction I.D or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. ☒
If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| | Large accelerated filer ☒ | | | Accelerated filer ☐ | | | Non-accelerated filer ☐ | | |
Smaller reporting company
☐
|
|
| | | | | | | | | | |
Emerging growth company
☐
|
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
CALCULATION OF REGISTRATION FEE
| | | |||||||||||||||||||||
|
Title of Each Class of Securities to be Registered(1)
|
| |
Amount to be
Registered(1) |
| |
Proposed Maximum
Offering Price Per Unit(2) |
| |
Proposed Maximum
Aggregate Offering Price(2) |
| |
Amount of
Registration Fee |
| |||||||||
|
Common Stock, par value $0.001 per share
|
| |
760,365
|
| | | $ | 48.45 | | | | | $ | 36,839,684.25 | | | | | $ | 4,781.80 | | |
(1)
The shares of common stock will be offered for resale by the selling stockholders. Pursuant to Rule 416 under the Securities Act, this Registration Statement also relates to an indeterminate number of additional shares of common stock to be issued as a result of stock splits, stock dividends or similar transactions.
(2)
Estimated solely for purposes of calculating the registration fee pursuant to Rule 457(c) under the Securities Act, based on the average of the high and low price per share of the common stock as reported on The Nasdaq Global Select Market on June 15, 2020.
PROSPECTUS
760,365 Shares
![[MISSING IMAGE: lg_ptctherapeutic-bw.jpg]](/stocks/ptct/documents/23f95c02-8c01-4524-aaf6-4bc6261b950c/asset/lg_ptctherapeutic-bw.jpg)
PTC Therapeutics, Inc.
Common Stock
This prospectus relates to resales of shares of common stock previously issued by PTC Therapeutics, Inc. to certain former securityholders of Censa Pharmaceuticals Inc., or Censa, in connection with our acquisition of Censa.
We will not receive any proceeds from the sale of the shares.
The selling stockholders identified in this prospectus, or their pledgees, assignees, donees, transferees or other successors-in-interest, may offer the shares from time to time through public or private transactions at prevailing market prices, at prices related to prevailing market prices or at privately negotiated prices.
Our common stock is traded on The Nasdaq Global Select Market under the symbol “PTCT.” On June 18, 2020, the closing sale price of the common stock on The Nasdaq Global Select Market was $50.36 per share. You are urged to obtain current market quotations for the common stock.
Investing in our common stock involves significant risks. See the information contained in this prospectus under the heading “Risk Factors” beginning on page
7 of this prospectus and in the documents incorporated by reference in this prospectus for a discussion of the factors you should carefully consider before deciding to purchase our common stock.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.
The date of this prospectus is June 19, 2020.
TABLE OF CONTENTS
| | | | | | 1 | | | |
| | | | | | 1 | | | |
| | | | | | 5 | | | |
| | | | | | 7 | | | |
| | | | | | 7 | | | |
| | | | | | 7 | | | |
| | | | | | 13 | | | |
| | | | | | 17 | | | |
| | | | | | 19 | | | |
| | | | | | 19 | | | |
| | | | | | 19 | | | |
| | | | | | 19 | | |
i
ABOUT THIS PROSPECTUS
This prospectus is part of a registration statement that we filed with the Securities and Exchange Commission, or the SEC. The selling stockholders may from time to time sell shares of common stock described in this prospectus.
This prospectus provides you with a description of the common stock selling stockholders may offer. You should read both this prospectus together with the additional information described under the heading “Where You Can Find More Information” beginning on page
19 of this prospectus.
We have not authorized anyone to provide you with information different from that contained in this prospectus, any accompanying prospectus supplement or in any related free writing prospectus filed by us with the SEC. We do not take any responsibility for, and cannot provide any assurance as to the reliability of, any information other than the information in this prospectus, any accompanying prospectus supplement or in any related free writing prospectus filed by us with the SEC. This prospectus does not constitute an offer to sell or the solicitation of an offer to buy any securities other than the securities described herein or an offer to sell or the solicitation of an offer to buy such securities in any circumstances in which such offer or solicitation is unlawful. The selling stockholders are offering to sell, and seeking offers to buy, shares of our common stock only in jurisdictions where offers and sales are permitted. You should assume that the information appearing in this prospectus, any prospectus supplement, the documents incorporated by reference and any related free writing prospectus is accurate only as of the respective dates of such documents. Our business, financial condition, results of operations and prospects may have changed materially since those dates.
Unless the context otherwise indicates, references in this prospectus to “PTC,” “we,” “our,” “us” and “the Company” refer, collectively, to PTC Therapeutics, Inc., a Delaware corporation, and its consolidated subsidiaries.
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
This prospectus and the information incorporated by reference in this prospectus include “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. All statements contained or incorporated by reference herein, including statements regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans, objectives of management and expected market growth, other than statements of historical facts, are forward-looking statements. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “predict,” “project,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.
The forward-looking statements in this prospectus and the information incorporated by reference herein and therein include, among other things, statements about:
•
expectations with respect to our gene therapy platform, including any potential regulatory submissions and potential approvals, including those related to our gene therapy for the treatment of Aromatic L-Amino Acid Decarboxylase, or AADC deficiency, or PTC-AADC, our manufacturing capabilities and the potential financial impact and benefits of our leased biologics manufacturing facility and the potential achievement of development, regulatory and sales milestones and contingent payments that we may be obligated to make;
•
our ability to negotiate, secure and maintain adequate pricing, coverage and reimbursement terms and processes on a timely basis, or at all, with third-party payors for our products or product candidates that we commercialize or may commercialize in the future;
•
our ability to maintain our marketing authorization of Translarna for the treatment of nonsense mutation Duchenne muscular dystrophy, or nmDMD, in the European Economic Area, or EEA, which is subject to the specific obligation to conduct and submit the results of Study 041 to the European Medicines Agency, or EMA, and annual review and renewal by the European Commission following reassessment of the benefit-risk balance of the authorization by the EMA;
1
•
our ability to enroll, fund, and complete Study 041, a multicenter, randomized, double-blind, 18-month, placebo-controlled clinical trial of Translarna for the treatment of nmDMD followed by an 18-month open label extension, according to the protocol agreed with the EMA, and by the EMA’s deadline;
•
the anticipated period of market exclusivity for Emflaza for the treatment of DMD in the United States under the Orphan Drug Act of 1983, the Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Act;
•
our ability to complete any dystrophin study necessary in order to resolve the matters set forth in the United States Food and Drug Administration’s, or the FDA, denial of our appeal to the Complete Response Letter we received from the FDA in connection with our New Drug Application, or NDA, for Translarna for the treatment of nmDMD, and our ability to perform additional clinical trials, non-clinical studies or CMC assessments or analyses at significant cost;
•
the timing and scope of our commercialization of our products and product candidates;
•
our expectations with respect to the novel coronavirus (COVID-19) pandemic and related response measures and their effects on our business, operations, clinical trials, potential regulatory submissions and approvals, our collaborators, contract research organizations, suppliers and manufacturers;
•
our ability to obtain additional and maintain existing reimbursed named patient and cohort early access programs for our products on adequate terms, or at all;
•
our expectations with respect to the development, regulatory and commercial status of our product candidates and program directed against spinal muscular atrophy in collaboration with F. Hoffmann La Roche Ltd and Hoffmann La Roche Inc., which we refer to collectively as Roche, and the Spinal Muscular Atrophy Foundation, or the SMA Foundation, and our estimates regarding future revenues from achievement of milestones in that program;
•
our expectations and the potential financial impact and benefits related to our Collaboration and Licensing Agreement with Akcea Therapeutics, Inc., or Akcea, including with respect to the timing of regulatory approval of TegsediTM (inotersen) and WaylivraTM (volanesorsen) in countries in which we are licensed to commercialize them, the commercialization of Tegsedi and Waylivra, and our expectations with respect to contingent payments to Akcea based on the potential achievement of certain regulatory milestones and royalty payments by us to Akcea based on our potential achievement of certain net sales thresholds;
•
our estimates regarding the potential market opportunity for our products or product candidates, including the size of eligible patient populations and our ability to identify such patients;
•
our estimates regarding expenses, future revenues, third-party discounts and rebates, capital requirements and needs for additional financing, including our ability to maintain the level of our expenses consistent with our internal budgets and forecasts and to secure additional funds on favorable terms or at all;
•
the timing and conduct of our ongoing, planned and potential future clinical trials and studies in our gene therapy, splicing, Bio-e and oncology programs as well as studies in our products for maintaining authorizations, label extensions and additional indications, including the timing of initiation, enrollment and completion of the trials and the period during which the results of the trials will become available;
•
our ability to realize the anticipated benefits of our acquisitions or other strategic transactions, including the possibility that the expected impact of benefits from the acquisitions or strategic transactions will not be realized or will not be realized within the expected time period, significant transaction costs, the integration of operations and employees into our business, our ability to obtain marketing approval of our product candidates we acquired from the acquisitions or other strategic transactions and unknown liabilities;
•
the rate and degree of market acceptance and clinical utility of any of our products or product candidates;
2
•
the ability and willingness of patients and healthcare professionals to access our products and product candidates through alternative means if pricing and reimbursement negotiations in the applicable territory do not have a positive outcome;
•
our ability to complete the FDA post-marketing requirements to the marketing authorization of Emflaza and any other post-marketing requirements for our products;
•
the timing of, and our ability to obtain additional marketing authorizations for our products and product candidates;
•
the ability of our products and our product candidates to meet existing or future regulatory standards;
•
our ability to maintain the current labeling under the marketing authorization in the EEA or expand the approved product label of Translarna for the treatment of nmDMD;
•
the potential receipt of revenues from future sales of our products or product candidates;
•
the potential impact that enrollment, funding and completion of Study 041 may have on our revenue growth;
•
our sales, marketing and distribution capabilities and strategy, including the ability of our third-party manufacturers to manufacture and deliver our products and product candidates in clinically and commercially sufficient quantities and the ability of distributors to process orders in a timely manner and satisfy their other obligations to us;
•
our ability to establish and maintain arrangements for the manufacture of our products and product candidates that are sufficient to meet clinical trial and commercial launch requirements;
•
our ability to establish and grow our manufacturing capabilities for our gene therapy platform;
•
our expectations with respect to the potential financial impact and benefits of our leased biologics manufacturing facility and our ability to satisfy our obligations under the terms of the lease agreement for such facility;
•
our ability to satisfy our obligations under the terms of the credit and security agreement with MidCap Financial Trust, or MidCap Financial, as administrative agent and MidCap Financial and certain other financial institutions as lenders thereunder;
•
our ability to satisfy our obligations under the indenture governing our 3.00% convertible senior notes due August 15, 2022 and under the indenture governing our 1.50% convertible senior notes due September 15, 2026;
•
our regulatory submissions, including with respect to timing and outcome of regulatory review;
•
our plans to advance our earlier stage programs and pursue research and development of other product candidates, including our splicing, gene therapy, Bio-e and oncology programs;
•
whether we may pursue business development opportunities, including potential collaborations, alliances, and acquisition or licensing of assets and our ability to successfully develop or commercialize any assets to which we may gain rights pursuant to such business development opportunities;
•
the potential advantages of our products and any product candidate;
•
our intellectual property position;
•
the impact of government laws and regulations;
•
the impact of litigation that has been or may be brought against us or of litigation that we are pursuing against others; and
•
our competitive position.
We may not actually achieve the plans, intentions or expectations expressed or implied in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. We have included important factors in the cautionary statements included in
3
this prospectus and the information incorporated by reference herein, particularly the factors set forth under the caption “Risk Factors” of this prospectus, under the caption “Risk Factors” in Part I, Item 1A of our
Annual Report on Form 10-K for the fiscal year ended December 31, 2019, and under the caption “Risk Factors” in Part II, Item 1A of our
Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2020, that we believe could cause actual results or events to differ materially from the forward-looking statements that we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments we make. We do not assume any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
4
PROSPECTUS SUMMARY
This summary highlights selected information contained elsewhere in this prospectus and in the documents we incorporate by reference. This summary does not contain all of the information you should consider before making an investment decision. You should read this entire prospectus carefully, especially the risks of investing in our common stock discussed under “Risk Factors” beginning on page
7 of this prospectus, under the caption “Risk Factors” in Part I, Item 1A of our
Annual Report on Form 10-K for the fiscal year ended December 31, 2019, and under the caption “Risk Factors” in Part II, Item 1A of our
Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2020, along with our consolidated financial statements and notes to those consolidated financial statements and the other information incorporated by reference in this prospectus.
PTC Therapeutics, Inc.
We are a science-driven global biopharmaceutical company focused on the discovery, development and commercialization of clinically-differentiated medicines that provide benefits to patients with rare disorders. Our ability to commercialize products is the foundation that drives our continued investment in a robust diversified pipeline of transformative medicines and our mission to provide access to best-in-class treatments for patients who have an unmet medical need. Our strategy is to bring best-in-class therapies with differentiated clinical benefit to patients affected by rare disorders and to leverage its our commercial infrastructure to maximize value for our patients and other stakeholders. We have a portfolio pipeline that includes commercial products as well as product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focused on the development of new treatments for multiple therapeutic areas, including rare diseases and oncology.
Acquisition of Censa Pharmaceuticals Inc.
On May 29, 2020, we acquired Censa, which prior to the acquisition was a privately-held biopharmaceutical company focused on the development and commercialization of PTC923 (formerly CNSA-001), a clinical-stage investigational therapy for orphan metabolic diseases, including phenylketonuria and other diseases associated with defects in the tetrahydrobiopterin biochemical pathways diagnosed at birth. The acquisition was effected pursuant to an Agreement and Plan of Merger, or the Merger Agreement, by and among us, Hydro Merger Sub, Inc., a Delaware corporation and a wholly owned, indirect subsidiary of the Company, Censa, and, solely in its capacity as the representative, agent and attorney-in-fact of the securityholders of Censa, Shareholder Representative Services LLC, a Colorado limited liability company and resulted in Censa becoming our wholly owned, indirect subsidiary.
The above descriptions of the Merger Agreement is a summary only and is qualified in their entirety by reference to the terms of the Merger Agreement, included as Exhibit 2.1 hereto.
Company Information
We were incorporated under the laws of the State of Delaware on March 31, 1998, under the name PTC Therapeutics, Inc. Our principal executive offices are located at 100 Corporate Court, South Plainfield, New Jersey 07080. Our telephone number is (908) 222-7000. We maintain a website at www.ptcbio.com. The information contained on, or that can be accessed through, our website is not a part of this prospectus. We have included our website address in this prospectus solely as an inactive textual reference.
5
The Offering
Common Stock Offered by the Selling Stockholders
760,365 shares
Use of Proceeds
We will not receive any proceeds from the sale of shares in this offering. See “Use of Proceeds” for more information
Risk Factors
You should read the “Risk Factors” section of this prospectus, as well as those risk factors incorporated by reference in this prospectus, for a discussion of factors to consider carefully before deciding to purchase shares of our common stock.
Nasdaq Global Select Market Symbol
“PTCT”
6
RISK FACTORS
Investing in our common stock involves significant risks. In deciding whether to invest, and in consultation with your own financial and legal advisors, you should carefully consider the risk factors and the risks described under the caption “Risk Factors” in Part I, Item 1A of our
Annual Report on Form 10-K for the fiscal year ended December 31, 2019, and under the caption “Risk Factors” in Part II, Item 1A of our
Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2020, as well as the other information contained in this prospectus and in our filings with the SEC that we have incorporated by reference in this prospectus. Any of these risks could have a material adverse effect on our business, financial condition, results of operations and prospects and cause the value of our stock to decline, which could cause you to lose all or part of your investment. The risks and uncertainties we have described are not the only ones facing us. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also affect our business operations.
USE OF PROCEEDS
We will not receive any proceeds from the sale of shares by the selling stockholders.
The selling stockholders will pay any underwriting discounts and commissions and expenses incurred by the selling stockholders for brokerage, accounting, tax, or legal services or any other expenses incurred by the selling stockholders in disposing of the shares. We will bear all other costs, fees and expenses incurred in effecting the registration of the shares covered by this prospectus, including, without limitation, all registration and filing fees, The Nasdaq Global Select Market listing fees, and fees and expenses of our counsel and our accountants.
SELLING STOCKHOLDERS
This prospectus relates to the resale of shares of our common stock held by the selling stockholders listed in the table below. The selling stockholders acquired these shares from us in a private offering pursuant to an exemption from registration afforded by Section 4(a)(2) of the Securities Act and/or Regulation D promulgated thereunder as partial consideration for our acquisition of Censa on May 29, 2020. Under the Merger Agreement, we agreed to file a registration statement on Form S-3 with the SEC for the purposes of registering for resale the shares of our common stock issued to the selling stockholders and to maintain the effectiveness of the registration statement until the six month anniversary date of the closing of the acquisition or such earlier time as all shares of common stock covered by the registration statement have been sold, subject to certain exceptions.
The following table sets forth, to our knowledge, certain information about the selling stockholders as of June 19, 2020.
Beneficial ownership is determined in accordance with the rules of the SEC and includes voting or investment power with respect to shares. Unless otherwise indicated below, to our knowledge, all persons named in the table have sole voting and investment power with respect to their shares of common stock, except to the extent authority is shared by spouses under applicable law. The inclusion of any shares in this table does not constitute an admission of beneficial ownership for the person named below.
|
Name of Selling Stockholders
|
| |
Shares of Common Stock
Beneficially Owned Prior to Offering |
| |
Number of Shares of
Common Stock Being Offered |
| |
Shares of Common Stock
to be Beneficially Owned After Offering(1) |
| |||||||||||||||||||||
| |
Number
|
| |
Percentage(2)
|
| |
Number
|
| |
Percentage
|
| ||||||||||||||||||||
|
Christopher Schelling†
|
| | | | 144,743(4) | | | | | | *% | | | | | | 144,743 | | | | | | 0 | | | | | | *% | | |
|
Joseph Baron†
|
| | | | 71,665(5) | | | | | | *% | | | | | | 71,665 | | | | | | 0 | | | | | | *% | | |
|
Jonathan Reis†#
|
| | | | 68,700(6) | | | | | | *% | | | | | | 68,700 | | | | | | 0 | | | | | | *% | | |
|
Jefferson Davis#
|
| | | | 42,451(7) | | | | | | *% | | | | | | 42,451 | | | | | | 0 | | | | | | *% | | |
|
Harry Palmin
|
| | | | 2,250(8) | | | | | | *% | | | | | | 2,250 | | | | | | 0 | | | | | | *% | | |
|
Benjamin Dewees
|
| | | | 29,622(9) | | | | | | *% | | | | | | 29,622 | | | | | | 0 | | | | | | *% | | |
7
|
Name of Selling Stockholders
|
| |
Shares of Common Stock
Beneficially Owned Prior to Offering |
| |
Number of Shares of
Common Stock Being Offered |
| |
Shares of Common Stock
to be Beneficially Owned After Offering(1) |
| |||||||||||||||||||||
| |
Number
|
| |
Percentage(2)
|
| |
Number
|
| |
Percentage
|
| ||||||||||||||||||||
|
Baron Family Investments, LLC
|
| | | | 23,519(10) | | | | | | *% | | | | | | 23,519 | | | | | | 0 | | | | | | *% | | |
|
InClin, Inc.
|
| | | | 47,870(11) | | | | | | *% | | | | | | 47,870 | | | | | | 0 | | | | | | *% | | |
|
Daniel Levy
|
| | | | 2,500(12) | | | | | | *% | | | | | | 2,500 | | | | | | 0 | | | | | | *% | | |
|
Keith Hyland
|
| | | | 534(13) | | | | | | *% | | | | | | 534 | | | | | | 0 | | | | | | *% | | |
|
Neil Smith#(3)
|
| | | | 9,144(14) | | | | | | *% | | | | | | 9,144 | | | | | | 0 | | | | | | *% | | |
|
The Reis Family Irrevocable Trust – 2018
|
| | | | 16,874(15) | | | | | | *% | | | | | | 16,874 | | | | | | 0 | | | | | | *% | | |
|
Michelle Skupien
|
| | | | 3,242(16) | | | | | | *% | | | | | | 3,242 | | | | | | 0 | | | | | | *% | | |
|
Andrew R Schelling Irrevocable Trust
|
| | | | 17,999(17) | | | | | | *% | | | | | | 17,999 | | | | | | 0 | | | | | | *% | | |
|
Lauren E Schelling Irrevocable Trust
|
| | | | 17,999(18) | | | | | | *% | | | | | | 17,999 | | | | | | 0 | | | | | | *% | | |
|
Robert Steiner
|
| | | | 2,738(19) | | | | | | *% | | | | | | 2,738 | | | | | | 0 | | | | | | *% | | |
|
Stuart Swiedler
|
| | | | 514(20) | | | | | | *% | | | | | | 514 | | | | | | 0 | | | | | | *% | | |
|
Scott Reynolds
|
| | | | 317(21) | | | | | | *% | | | | | | 317 | | | | | | 0 | | | | | | *% | | |
|
Stephen J. Aselage
|
| | | | 5,727(22) | | | | | | *% | | | | | | 5,727 | | | | | | 0 | | | | | | *% | | |
|
Helge Reisch#(3)
|
| | | | 2,072(23) | | | | | | *% | | | | | | 2,072 | | | | | | 0 | | | | | | *% | | |
|
MNT Investments (Cyprus) LTD
|
| | | | 25,889(24) | | | | | | *% | | | | | | 25,889 | | | | | | 0 | | | | | | *% | | |
|
Jacque K. Davis
|
| | | | 3,127(25) | | | | | | *% | | | | | | 3,127 | | | | | | 0 | | | | | | *% | | |
|
Boden Family Investments, LLC
|
| | | | 6,300(26) | | | | | | *% | | | | | | 6,300 | | | | | | 0 | | | | | | *% | | |
|
Daniel Gressel
|
| | | | 14,474(27) | | | | | | *% | | | | | | 14,474 | | | | | | 0 | | | | | | *% | | |
|
Robert Fischetti
|
| | | | 3,915(28) | | | | | | *% | | | | | | 3,915 | | | | | | 0 | | | | | | *% | | |
|
David Reis
|
| | | | 6,300(29) | | | | | | *% | | | | | | 6,300 | | | | | | 0 | | | | | | *% | | |
|
Timothy D. Miller
|
| | | | 12,944(30) | | | | | | *% | | | | | | 12,944 | | | | | | 0 | | | | | | *% | | |
|
Millennium Trust Co., LLC
CUSTODIAN FBO |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|
Robert T. Davis IRA xxxx44969
|
| | | | 1,875(31) | | | | | | *% | | | | | | 1,875 | | | | | | 0 | | | | | | *% | | |
|
Agha Shahid Khan
|
| | | | 7,499(32) | | | | | | *% | | | | | | 7,499 | | | | | | 0 | | | | | | *% | | |
|
Rizwan Kirmani
|
| | | | 3,749(33) | | | | | | *% | | | | | | 3,749 | | | | | | 0 | | | | | | *% | | |
|
Arkin Bio Ventures LP
|
| | | | 144,690(34) | | | | | | *% | | | | | | 144,690 | | | | | | 0 | | | | | | *% | | |
|
Arnold Wong
|
| | | | 3,825(35) | | | | | | *% | | | | | | 3,825 | | | | | | 0 | | | | | | *% | | |
|
Darryl Phelps
|
| | | | 3,825(36) | | | | | | *% | | | | | | 3,825 | | | | | | 0 | | | | | | *% | | |
|
Sandra Suoka Chen
|
| | | | 1,274(37) | | | | | | *% | | | | | | 1,274 | | | | | | 0 | | | | | | *% | | |
|
Taylor Kilfoil
|
| | | | 3,825(39) | | | | | | *% | | | | | | 3,825 | | | | | | 0 | | | | | | *% | | |
|
Amir Caspari
|
| | | | 2,550(40) | | | | | | *% | | | | | | 2,550 | | | | | | 0 | | | | | | *% | | |
|
David Dove
|
| | | | 2,550(41) | | | | | | *% | | | | | | 2,550 | | | | | | 0 | | | | | | *% | | |
|
Laurens Cook
|
| | | | 1,274(42) | | | | | | *% | | | | | | 1,274 | | | | | | 0 | | | | | | *% | | |
*
Less than 1%.
#
Employee or former employee of us or Censa.
†
Former member of the board of directors of Censa.
(1)
We do not know when or in what amounts a selling stockholder may offer shares for sale. The selling stockholders might not sell any or all of the shares offered by this prospectus. Because the selling stockholders may offer all or some of the shares pursuant to this offering, and because there are currently no agreements, arrangements or understandings with respect to the sale of any of the shares, we
8
cannot estimate the number of the shares that will be held by the selling stockholders after completion of the offering. However, for purposes of this table, we have assumed that, after completion of the offering, none of the shares covered by this prospectus will be held by the selling stockholders and that the number of shares otherwise held by the selling stockholders and not covered by this prospectus remains the same after completion of the offering.
(2)
Based on 65,479,703 shares of our common stock outstanding on May 29, 2020.
(3)
Received an inducement grant for non-statutory stock options and restricted stock units from us pursuant to the Nasdaq inducement grant exception and our 2020 Inducement Stock Incentive Plan on June 10, 2020.
(4)
Consists of 144,743 shares of common stock issued to the selling stockholder pursuant to the Merger Agreement and registered hereby. The selling stockholder is a former member of the board of directors of Censa. The address of the selling stockholder is 3068 NW Duffy Drive, Bend, OR 97703.
(5)
Consists of 71,665 shares of common stock issued to the selling stockholder pursuant to the Merger Agreement and registered hereby. The selling stockholder is a former member of the board of directors of Censa. The address of the selling stockholder is 31 Shirley Rd, Wellesley, MA, 02482.
(6)
Consists of 68,700 shares of common stock issued to the selling stockholder pursuant to the Merger Agreement and registered hereby. The selling stockholder is a former member of the board of directors of Censa and prior to the acquisition served as the President and Chief Executive Officer of Censa. The address of the selling stockholder is 146 Winthrop Road, Brookline, MA, 02445.
(7)
Consists of 42,451 shares of common stock issued to the selling stockholder pursuant to the Merger Agreement and registered hereby. Prior to the acquisition the selling stockholder served as Vice President, Corporate Development of Censa. The address of the selling stockholder is 513 Strawberry Hill Road, Concord, MA, 01742.
(8)
Consists of 2,250 shares of common stock issued to the selling stockholder pursuant to the Merger Agreement and registered hereby. The address of the selling stockholder is 51 Helene Road, Waban, MA, 02468.
(9)
Consists of 29,622 shares of common stock issued to the selling stockholder pursuant to the Merger Agreement and registered hereby. The address of the selling stockholder is 1225 Pickett St., Sonoma, CA, 95476.
(10)
Consists of 23,519 shares of common stock issued to the selling stockholder pursuant to the Merger Agreement and registered hereby. The address of the selling stockholder is 31 Shirley Rd, Wellesley, MA, 02482. Voting and investment control over the shares is held by Joseph Baron, as the managing member of the selling stockholder.
(11)
Consists of 47,870 shares of common stock issued to the selling stockholder pursuant to the Merger Agreement and registered hereby. The address of the selling stockholder is 2655 Campus Drive, San Mateo, CA, 94403. Arnold Wong is the Chief Financial Officer of the selling stockholder.
(12)
Consists of 2,500 shares of common stock issued to the selling stockholder pursuant to the Merger Agreement and registered hereby. The address of the selling stockholder is 490 Summerfield Way, San Mateo, CA, 94402.
(13)
Consists of 534 shares of common stock issued to the selling stockholder pursuant to the Merger Agreement and registered hereby. The address of the selling stockholder is 37 Lakewood Circle, Venice, FL, 34292.
(14)
Consists of 9,144 shares of common stock issued to the selling stockholder pursuant to the Merger Agreement and registered hereby. Prior to the acquisition the selling stockholder served as Vice President, Research and Development and Head of Operations of Censa and currently serves as our Vice President, Product Owner. The address of the selling stockholder is 6709 Millory Springs Ln, Cary, NC, 27519.
(15)
Consists of 16,874 shares of common stock issued to the selling stockholder pursuant to the Merger Agreement and registered hereby. The address of the selling stockholder is Fidelity Personal Trust Company, FSB, 2 Contra Way, Merrimack, NH, 03054. Voting and investment control over the shares is held by Fidelity Personal Trust Company, FSB, trustee.
9
(16)
Consists of 3,242 shares of common stock issued to the selling stockholder pursuant to the Merger Agreement and registered hereby. The address of the selling stockholder is 71 Marlborough Street #2, Boston, MA, 02116.
(17)
Consists of 17,999 shares of common stock issued to the selling stockholder pursuant to the Merger Agreement and registered hereby. The address of the selling stockholder is 3068 NW Duffy Drive, Bend, OR, 97703. Voting and investment control over the shares is held by Aaron Schelling, trustee.
(18)
Consists of 17,999 shares of common stock issued to the selling stockholder pursuant to the Merger Agreement and registered hereby. The address of the selling stockholder is 3068 NW Duffy Drive, Bend, OR, 97703. Voting and investment control over the shares is held by Aaron Schelling, trustee.
(19)
Consists of 2,738 shares of common stock issued to the selling stockholder pursuant to the Merger Agreement and registered hereby. The address of the selling stockholder is 205500 Fox Fire Lane, Marshfield, WI, 54449.
(20)
Consists of 514 shares of common stock issued to the selling stockholder pursuant to the Merger Agreement and registered hereby. The address of the selling stockholder is 6012 Auburn Ave, Oakland, CA, 94618.
(21)
Consists of 317 shares of common stock issued to the selling stockholder pursuant to the Merger Agreement and registered hereby. The address of the selling stockholder is 21 Mount Airy Road, Pipersville, PA, 18947.
(22)
Consists of 5,727 shares of common stock issued to the selling stockholder pursuant to the Merger Agreement and registered hereby. The address of the selling stockholder is PO Box 3141, RSF, CA, 92067.
(23)
Consists of 2,072 shares of common stock issued to the selling stockholder pursuant to the Merger Agreement and registered hereby. Prior to the acquisition the selling stockholder served as Vice President of CMC of Censa and currently serves as our Vice President, Technical Operations. The address of the selling stockholder is 36 Wells St., Westerly, RI, 02891.
(24)
Consists of 25,889 shares of common stock issued to the selling stockholder pursuant to the Merger Agreement and registered hereby. The address of the selling stockholder is Agias Fylaxeos 95, 3087, Limassol, Cyprus
(25)
Consists of 3,127 shares of common stock issued to the selling stockholder pursuant to the Merger Agreement and registered hereby. The address of the selling stockholder is 2100 Bradford Mill CT, Apex,
NC, 27539.
NC, 27539.
(26)
Consists of 6,300 shares of common stock issued to the selling stockholder pursuant to the Merger Agreement and registered hereby. The address of the selling stockholder is 2842 Cravey Drive, Atlanta,
GA, 30345.
GA, 30345.
(27)
Consists of 14,474 shares of common stock issued to the selling stockholder pursuant to the Merger Agreement and registered hereby. The address of the selling stockholder is 88 Cedar Cliff Road, Riverside,
CT, 06878.
CT, 06878.
(28)
Consists of 3,915 shares of common stock issued to the selling stockholder pursuant to the Merger Agreement and registered hereby. The address of the selling stockholder is 7 Lockwood Drive, Old Greenwich, CT, 06870.
(29)
Consists of 6,300 shares of common stock issued to the selling stockholder pursuant to the Merger Agreement and registered hereby. The address of the selling stockholder is 15 Yitzchak Elhanan Street, Apt. 261, Tel-Aviv 6525015, Israel.
(30)
Consists of 12,944 shares of common stock issued to the selling stockholder pursuant to the Merger Agreement and registered hereby. The address of the selling stockholder is 10730 Graeloch Rd., Laurel, MD, 20723.
(31)
Consists of 1,875 shares of common stock issued to the selling stockholder pursuant to the Merger Agreement and registered hereby. The address of the selling stockholder is 2001 Spring Road, Suite 700, Oak Brook, IL, 60523.
(32)
Consists of 7,499 shares of common stock issued to the selling stockholder pursuant to the Merger Agreement and registered hereby. The address of the selling stockholder is 2411 W. Belvedere Ave, S-402, Balto, MD, 21215.
10
(33)
Consists of 3,749 shares of common stock issued to the selling stockholder pursuant to the Merger Agreement and registered hereby. The address of the selling stockholder is 3623 Chesapeake St., NW, Washington, DC, 20008.
(34)
Consists of 144,690 shares of common stock issued to the selling stockholder pursuant to the Merger Agreement and registered hereby. The address of the selling stockholder is Hachoshlim, 6 Herzliya, Israel.
(35)
Consists of 3,825 shares of common stock issued to the selling stockholder pursuant to the Merger Agreement and registered hereby. The address of the selling stockholder is 13163 Diericx Drive, Moutnain View, CA, 94040.
(36)
Consists of 3,825 shares of common stock issued to the selling stockholder pursuant to the Merger Agreement and registered hereby. The address of the selling stockholder is 8 Shackwell Ct, Danville, CA, 94506.
(37)
Consists of 1,274 shares of common stock issued to the selling stockholder pursuant to the Merger Agreement and registered hereby. The address of the selling stockholder is 1549 Tobias Drive, San Jose, CA, 95118.
(38)
Consists of 3,825 shares of common stock issued to the selling stockholder pursuant to the Merger Agreement and registered hereby. The address of the selling stockholder is 21 Ryries Parade, Cremorne, NSW 2090, Australia.
(39)
Consists of 2,550 shares of common stock issued to the selling stockholder pursuant to the Merger Agreement and registered hereby. The address of the selling stockholder is 31 Ahad Haam Street, Tel Aviv 6520204, Israel.
(40)
Consists of 2,550 shares of common stock issued to the selling stockholder pursuant to the Merger Agreement and registered hereby. The address of the selling stockholder is 7241 E. Ventana Canyon Drive, Tuscon, AZ, 85750.
(41)
Consists of 1,274 shares of common stock issued to the selling stockholder pursuant to the Merger Agreement and registered hereby. The address of the selling stockholder is 70 Chestnut St, Boston, MA, 02108.
Relationships with Selling Stockholders
None of the selling stockholders has had a material relationship with us or any of our subsidiaries within the past three years except as set forth below or in the table above or the notes thereto.
None of the selling stockholders has held any position or office with us or any of our subsidiaries within the past three years, except that the selling stockholders indicated below or in the table above or the notes thereto have been employed by us and/or Censa. In connection with our acquisition of Censa, Helge Reisch, formerly Vice President of CMC of Censa, and Neil Smith, formerly Vice President R&D and Head of Operations of Censa, entered into employment arrangements with the Company. Under their respective employment agreement, Mr. Smith will serve as Global Project Leader and Mr. Reisch will serve as Vice President, Technical Operations. Each of Mr. Smith and Mr. Reisch will receive an annual base salary and will be eligible to receive an annual discretionary bonus and an annual equity grant commensurate with and on the same terms as other comparable employees. Pursuant to their respective employment agreement, each of Mr. Smith and Mr. Reisch also received inducement grants of options to purchase 24,700 shares of our common stock and 1,740 restricted stock units. The employment agreements with Mr. Smith and Mr. Reisch also include certain other customary terms.
In addition to the shares of common stock being registered hereby, each of the selling stockholders received its pro rata portion of the cash consideration in connection with the closing of the acquisition. Under the Merger Agreement, each selling stockholder will also be entitled to receive its pro rata portion of contingent payments from the Company based on (i) the achievement of certain development and regulatory milestones up to an aggregate maximum amount of $217.5 million for PTC923’s two most advanced programs and receipt of a priority review voucher from the U.S. Food and Drug Administration as set forth in the Merger Agreement, (ii) $109 million in development and regulatory milestones for each additional indication of PTC923, (iii) the achievement of certain net sales milestones up to an aggregate
11
maximum amount of $160.0 million, (iv) a percentage of annual net sales during specified terms, ranging from single to low double digits of the applicable net sales threshold amount, and (v) any sublicense fees paid to the Company in consideration of any sublicense of Censa’s intellectual property to commercialize PTC923, on a country-by-country basis, which contingent payment shall equal to a mid-double digit percentage of any such sublicense fees. Pursuant to the Merger Agreement, the Company has the option to pay the initial $30 million development milestone, for the completion of enrollment of a Phase 3 clinical trial for the PTC923 for phenylketonuria, if achieved, in cash or shares of the Company’s common stock, or the Initial Milestone.
To the extent that we choose to pay the Initial Milestone with shares of our common stock, we will issue such shares to the selling stockholders in a private offering pursuant to an exemption from registration afforded by Section 4(a)(2) of the Securities Act and/or Regulation D promulgated thereunder, and have agreed to file another registration statement on Form S-3 with the SEC for the purposes of registering for resale of such shares within 30 days of the date of the milestone notice for the Initial Milestone and to maintain the effectiveness of such registration statement until the six month anniversary date of the date of the milestone notice for the Initial Milestone or such earlier time as all shares of common stock covered by such registration statement have been sold, subject to certain exceptions.
Under the Merger Agreement, we will indemnify each selling stockholder against any damages to which a selling stockholder may become subject by reason of any material misstatement or omission in this registration statement, except to the extent that such damages arise out of or are based upon information furnished to us by or on behalf of Censa or a Censa Securityholder for use in this registration statement. Each selling stockholder will indemnify us and certain related persons against any damages to which such indemnified parties may become subject by reason of any material misstatement or omission in this registration statement or any violation or alleged violation of the Securities Act, the Exchange Act, or any state securities law, or any rule promulgated under any of the foregoing, in each case to the extent based upon any action or omission made in reliance upon information provided by such selling stockholder for use in this registration statement.
Each selling stockholder also entered into a Joinder Agreement, under which such selling stockholder has agreed that, without our prior written consent and during the period (i) commencing at the merger effective time and ending on August 27, 2020 for the shares of our common stock received at merger closing, and (ii) within 60 days after the issuance of Initial Milestone shares to the extent we choose to pay the Initial Milestone using shares of our common stock, such selling stockholder will not, directly or indirectly, transfer any such shares of our common stock or enter into any contract, option or other arrangement or understanding with respect to any transfer (whether by actual disposition or effective economic disposition due to hedging, cash settlement or otherwise) of such shares of our common stock, except certain permitted transfers subject to certain conditions, and provided that the lock-up provisions described above will lapse (i) (A) with respect to one-third of the shares of our common stock received at merger closing, on June 28, 2020 and (B) with respect to an additional one-third of the shares of our common stock received at merger closing, on July 28, 2020, and (ii) with respect to fifty percent of the shares of our common stock received as Initial Milestone payment, if any, on the date that is 30 days after the date such shares are issued.
The foregoing description of the Merger Agreement is a summary only and is qualified in its entirety by reference to the terms of the Merger Agreement, included as Exhibit 2.1 hereto.
12
DESCRIPTION OF CAPITAL STOCK
The following description of our capital stock is intended as a summary only. This description is based upon, and is qualified by reference to, our restated certificate of incorporation, our amended and restated bylaws and applicable provisions of Delaware corporate law. This summary is not complete. You should read our restated certificate of incorporation and amended and restated bylaws, which are filed as exhibits to the registration statement of which this prospectus forms a part, for the provisions that are important to you.
Our authorized capital stock consists of 125,000,000 shares of common stock and 5,000,000 shares of preferred stock. As of May 29, 2020, there were 65,479,703 shares of common stock outstanding and no shares of preferred stock outstanding.
Common Stock
Voting Rights. Holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders and do not have cumulative voting rights. Each election of directors by our stockholders will be determined by a plurality of the votes cast by the stockholders entitled to vote on the election. In general, except (1) for the election of directors, (2) as described below under “— Provisions of Our Certificate of Incorporation and Bylaws and Delaware Law That May Have Anti-Takeover Effects — Super-Majority Voting,” (3) in the future to the extent that we have two or more classes or series of stock outstanding with separate voting rights and (4) as otherwise required by law, any matter to be voted on by our stockholders at any meeting is decided by the vote of the holders of a majority in voting power of the votes cast by the holders of shares of our stock present or represented at the meeting and voting affirmatively or negatively on such matter.
Dividends. Holders of common stock are entitled to receive proportionately any dividends as may be declared by our board of directors, subject to any preferential dividend rights of outstanding preferred stock.
Liquidation and Dissolution. In the event of our liquidation or dissolution, the holders of our common stock are entitled to receive proportionately all assets available for distribution to stockholders after the payment of all debts and other liabilities and subject to the prior rights of any of our outstanding preferred stock.
Other Rights. Holders of our common stock have no preemptive, subscription, redemption or conversion rights. The rights, preferences and privileges of holders of our common stock are subject to and may be adversely affected by the rights of the holders of shares of any series of our preferred stock that we may designate and issue in the future.
Transfer Agent and Registrar. American Stock Transfer & Trust Company, LLC is the transfer agent and registrar for our common stock.
Nasdaq Global Select Market. Our common stock is listed on The Nasdaq Global Select Market under the symbol “PTCT.”
Preferred Stock
Under the terms of our certificate of incorporation, our board of directors is authorized to issue shares of preferred stock in one or more series without stockholder approval, subject to any limitations imposed by the Nasdaq Marketplace Rules. Our board of directors has the discretion to determine the rights, preferences, privileges and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences, of each series of preferred stock. The purpose of authorizing our board of directors to issue preferred stock and determine its rights and preferences is to eliminate delays associated with a stockholder vote on specific issuances. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions, future financings and other corporate purposes, could have the effect of making it more difficult for a third party to acquire, or could discourage a third party from seeking to acquire, a majority of our outstanding voting stock. Currently, we have no shares of preferred stock outstanding.
13
Stock Options and Warrants
As of March 31, 2020, we had (i) issued and outstanding options to purchase 12,670,068 shares of our common stock at a weighted average exercise price of $34.95 per share and (ii) 927,151 shares of our common stock issuable upon the vesting of outstanding restricted stock awards and restricted stock units.
Convertible Notes
In August 2015, we issued, at par value, $150.0 million aggregate principal amount of 3.0% convertible senior notes due 2022, or the 2022 Convertible Notes. The 2022 Convertible Notes bear cash interest at a rate of 3.0% per year, payable semi-annually on February 15 and August 15 of each year, beginning on February 15, 2016. The 2022 Convertible Notes will mature on August 15, 2022, unless earlier repurchased or converted. The conversion rate for the 2022 Convertible Notes was initially, and remains, 17.7487 shares of our common stock per $1,000 principal amount of the 2022 Convertible Notes, which is equivalent to an initial conversion price of approximately $56.34 per share of our common stock.
In September 2019, we issued, at par value, $287.5 million aggregate principal amount of 1.5% convertible senior notes due 2026, or the 2026 Convertible Notes. The 2026 Convertible Notes bear cash interest at a rate of 1.50% per year, payable semi-annually on March 15 and September 15 of each year, beginning on March 15, 2020. The 2026 Convertible Notes will mature on September 15, 2026, unless earlier repurchased or converted. The conversion rate for the 2026 Convertible Notes was initially, and remains, 19.0404 shares of our common stock per $1,000 principal amount of the 2026 Convertible Notes, which is equivalent to an initial conversion price of approximately $52.52 per share of our common stock.
Effects of Authorized but Unissued Stock
We have shares of common stock and preferred stock available for future issuance without stockholder approval, subject to any limitations imposed by the listing standards of the Nasdaq Global Select Market. We may utilize these additional shares for a variety of corporate purposes, including for future public offerings to raise additional capital or facilitate corporate acquisitions or for payment as a dividend on our capital stock. The existence of unissued and unreserved common stock and preferred stock may enable our board of directors to issue shares to persons friendly to current management or to issue preferred stock with terms that could have the effect of making it more difficult for a third party to acquire, or could discourage a third party from seeking to acquire, a controlling interest in our company by means of a merger, tender offer, proxy contest or otherwise. In addition, if we issue preferred stock, the issuance could adversely affect the voting power of holders of common stock and the likelihood that such holders will receive dividend payments and payments upon liquidation.
Provisions of Our Certificate of Incorporation and Bylaws and Delaware Law That May Have Anti-Takeover Effects
Delaware Law. We are subject to Section 203 of the Delaware General Corporation Law. Subject to certain exceptions, Section 203 prevents a publicly held Delaware corporation from engaging in a “business combination” with any “interested stockholder” for three years following the date that the person became an interested stockholder, unless either the interested stockholder attained such status with the approval of our board of directors, the business combination is approved by our board of directors and stockholders in a prescribed manner or the interested stockholder acquired at least 85% of our outstanding voting stock in the transaction in which it became an interested stockholder. A “business combination” includes, among other things, a merger or consolidation involving us and the “interested stockholder” and the sale of more than 10% of our assets. In general, an “interested stockholder” is any entity or person beneficially owning 15% or more of our outstanding voting stock and any entity or person affiliated with or controlling or controlled by such entity or person. The restrictions contained in Section 203 are not applicable to any of our existing stockholders that owned 15% or more of our outstanding voting stock upon the closing of our initial public offering.
Staggered Board; Removal of Directors. Our certificate of incorporation and our bylaws divide our board of directors into three classes with staggered three-year terms. In addition, our certificate of incorporation and our bylaws provide that directors may be removed only for cause and only by the
14
affirmative vote of the holders of 75% of our shares of capital stock present in person or by proxy and entitled to vote. Under our certificate of incorporation and bylaws, any vacancy on our board of directors, including a vacancy resulting from an enlargement of our board of directors, may be filled only by vote of a majority of our directors then in office. Furthermore, our certificate of incorporation provides that the authorized number of directors may be changed only by the resolution of our board of directors. The classification of our board of directors and the limitations on the ability of our stockholders to remove directors, change the authorized number of directors and fill vacancies could make it more difficult for a third party to acquire, or discourage a third party from seeking to acquire, control of our company.
Stockholder Action; Special Meeting of Stockholders; Advance Notice Requirements for Stockholder Proposals and Director Nominations. Our certificate of incorporation and our bylaws provide that any action required or permitted to be taken by our stockholders at an annual meeting or special meeting of stockholders may only be taken if it is properly brought before such meeting and may not be taken by written action in lieu of a meeting. Our certificate of incorporation and our bylaws also provide that, except as otherwise required by law, special meetings of the stockholders can only be called by our chairman of the board, our president or chief executive officer or our board of directors. In addition, our bylaws establish an advance notice procedure for stockholder proposals to be brought before an annual meeting of stockholders, including proposed nominations of candidates for election to our board of directors. Stockholders at an annual meeting may only consider proposals or nominations specified in the notice of meeting or brought before the meeting by or at the direction of our board of directors, or by a stockholder of record on the record date for the meeting, who is entitled to vote at the meeting and who has delivered timely written notice in proper form to our secretary of the stockholder’s intention to bring such business before the meeting. These provisions could have the effect of delaying until the next stockholder meeting stockholder actions that are favored by the holders of a majority of our outstanding voting securities. These provisions also could discourage a third party from making a tender offer for our common stock, because even if it acquired a majority of our outstanding voting stock, it would be able to take action as a stockholder, such as electing new directors or approving a merger, only at a duly called stockholders meeting and not by written consent.
Super-Majority Voting. The Delaware General Corporation Law provides generally that the affirmative vote of a majority of the shares entitled to vote on any matter is required to amend a corporation’s certificate of incorporation or bylaws, unless a corporation’s certificate of incorporation or bylaws, as the case may be, requires a greater percentage. Our bylaws may be amended or repealed by a majority vote of our board of directors or the affirmative vote of the holders of at least 75% of the votes that all our stockholders would be entitled to cast in any annual election of directors. In addition, the affirmative vote of the holders of at least 75% of the votes that all our stockholders would be entitled to cast in any election of directors is required to amend or repeal or to adopt any provisions inconsistent with any of the provisions of our certificate of incorporation described above.
Directors’ Liability
Our certificate of incorporation limits the personal liability of directors for breach of fiduciary duty to the maximum extent permitted by the Delaware General Corporation Law and provides that no director will have personal liability to us or to our stockholders for monetary damages for breach of fiduciary duty or other duty as a director. However, these provisions do not eliminate or limit the liability of any of our directors:
•
for any breach of the director’s duty of loyalty to us or our stockholders;
•
for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law;
•
for voting or assenting to unlawful payments of dividends, stock repurchases or other distributions; or
•
for any transaction from which the director derived an improper personal benefit.
Any amendment to or repeal of these provisions will not eliminate or reduce the effect of these provisions in respect of any act, omission or claim that occurred or arose prior to such amendment or repeal. If the Delaware General Corporation Law is amended to provide for further limitations on the
15
personal liability of directors of corporations, then the personal liability of our directors will be further limited to the greatest extent permitted by the Delaware General Corporation Law.
In addition, our certificate of incorporation provides that we must indemnify our directors and officers and we must advance expenses, including attorneys’ fees, to our directors and officers in connection with legal proceedings, subject to very limited exceptions.
We maintain a general liability insurance policy that covers certain liabilities of our directors and officers arising out of claims based on acts or omissions in their capacities as directors or officers. In addition, we have entered into indemnification agreements with our directors. These indemnification agreements may require us, among other things, to indemnify each such director for some expenses, including attorneys’ fees, judgments, fines and settlement amounts incurred by him in any action or proceeding arising out of his service as one of our directors.
Certain of our non-employee directors may, through their relationships with their employers, be insured and/or indemnified against certain liabilities incurred in their capacity as members of our board of directors.
16
PLAN OF DISTRIBUTION
The shares covered by this prospectus may be offered and sold from time to time by the selling stockholders. The term “selling stockholders” includes donees, pledgees, assignees, transferees or other successors-in-interest selling shares received after the date of this prospectus from a selling stockholder as a gift, pledge, partnership distribution or other non-sale related transfer. The selling stockholders will act independently of us in making decisions with respect to the timing, manner and size of each sale. Such sales may be made on one or more exchanges in any market or trading facility on which the shares are traded, or in the over-the-counter market or otherwise, at fixed prices, at prices and under terms then prevailing or at prices related to the then current market price or in negotiated transactions. The selling stockholders may sell their shares by one or more of, or a combination of, the following methods:
•
purchases by a broker-dealer as principal and resale by such broker-dealer for its own account pursuant to this prospectus;
•
ordinary brokerage transactions and transactions in which the broker solicits purchasers;
•
block trades in which the broker-dealer so engaged will attempt to sell the shares as agent but may position and resell a portion of the block as principal to facilitate the transaction;
•
an over-the-counter distribution in accordance with the rules of The Nasdaq Global Select Market;
•
through one or more underwritten offerings on a firm commitment or best efforts basis;
•
in privately negotiated transactions; and
•
in options transactions.
In addition, any shares that qualify for sale pursuant to Rule 144 may be sold under Rule 144 rather than pursuant to this prospectus.
To the extent required, this prospectus may be amended or supplemented from time to time to describe a specific plan of distribution. In connection with distributions of the shares or otherwise, the selling stockholders may enter into hedging transactions with broker-dealers or other financial institutions. In connection with such transactions, broker-dealers or other financial institutions may engage in short sales of the common stock in the course of hedging the positions they assume with selling stockholders. The selling stockholders may also sell the common stock short and redeliver the shares to close out such short positions. The selling stockholders may also enter into option or other transactions with broker-dealers or other financial institutions which require the delivery to such broker-dealer or other financial institution of shares offered by this prospectus, which shares such broker-dealer or other financial institution may resell pursuant to this prospectus. The selling stockholders may also pledge or grant a security interest in shares to a broker-dealer, other financial institution or other person, and, upon a default such pledgee or secured parties may effect sales of the pledged shares pursuant to this prospectus.
In effecting sales, broker-dealers or agents engaged by the selling stockholders may arrange for other broker-dealers to participate. Broker-dealers or agents may receive commissions, discounts or concessions from the selling stockholders in amounts to be negotiated immediately prior to the sale. Except as set forth in this prospectus under the heading “Selling Stockholders,” each selling stockholder has informed us that it is not a registered broker-dealer or an affiliate of a registered broker-dealer.
In offering the shares covered by this prospectus, the selling stockholders and any broker-dealers who execute sales for the selling stockholders may be deemed to be “underwriters” within the meaning of the Securities Act in connection with such sales. Any profits realized by the selling stockholders and the compensation of any broker-dealer may be deemed to be underwriting discounts and commissions. Any selling stockholder who is an “underwriter” within the meaning of the Securities Act will be subject to the prospectus delivery requirements of the Securities Act and the provisions of the Exchange Act and the rules thereunder relating to stock manipulation.
In order to comply with the securities laws of certain states, if applicable, the shares must be sold in such jurisdictions only through registered or licensed brokers or dealers. In addition, in certain states the shares may not be sold unless they have been registered or qualified for sale in the applicable state or an exemption from the registration or qualification requirement is available and is complied with.
17
We have advised the selling stockholders that the anti-manipulation rules of Regulation M under the Exchange Act may apply to sales of shares in the market and to the activities of the selling stockholders and their affiliates. In addition, we will make copies of this prospectus available to the selling stockholders for the purpose of satisfying the prospectus delivery requirements of the Securities Act. The selling stockholders may indemnify any broker-dealer that participates in transactions involving the sale of the shares against certain liabilities, including liabilities arising under the Securities Act.
At the time a particular offer of shares is made, if required, a prospectus supplement will be distributed that will set forth the number of shares being offered and the terms of the offering, including the name of any underwriter, dealer or agent, the purchase price paid by any underwriter, any discount, commission and other item constituting compensation, any discount, commission or concession allowed or reallowed or paid to any dealer, and the proposed selling price to the public.
We have agreed to indemnify the selling stockholders against certain liabilities, including certain liabilities under the Securities Act.
We have agreed with the selling stockholders to keep the Registration Statement of which this prospectus constitutes a part effective until the earlier of (i) such time as all of the shares covered by this prospectus have been disposed of pursuant to and in accordance with the Registration Statement or (ii) November 29, 2020.
18
LEGAL MATTERS
The validity of the shares offered by this prospectus has been passed upon by Morgan, Lewis & Bockius LLP, Philadelphia, Pennsylvania.
EXPERTS
Ernst & Young LLP, independent registered public accounting firm, has audited our consolidated financial statements included in our
Annual Report on Form 10-K for the year ended December 31, 2019, and the effectiveness of our internal control over financial reporting as of December 31, 2019, as set forth in their reports, which are incorporated by reference in this prospectus and elsewhere in the registration statement. Our financial statements are incorporated by reference in reliance on Ernst & Young LLP’s reports, given on their authority as experts in accounting and auditing.
The financial statements of Agilis Biotherapeutics, Inc. as of and for the years ended December 31, 2017 and 2016, incorporated in this prospectus by reference from our
Current Report on Form 8-K filed August 24, 2018 have been audited by BDO USA, LLP, independent auditors, as stated in their report, which is incorporated herein by reference. Such financial statements have been so incorporated in reliance upon the report of such firm given upon their authority as experts in accounting and auditing.
WHERE YOU CAN FIND MORE INFORMATION
We file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the public over the Internet at the SEC’s website at http://www.sec.gov. Copies of certain information filed by us with the SEC are also available on our website at http://www.ptcbio.com. Our website is not a part of this prospectus and is not incorporated by reference in this prospectus.
This prospectus is part of a registration statement we filed with the SEC. This prospectus omits some information contained in the registration statement in accordance with SEC rules and regulations. You should review the information and exhibits in the registration statement for further information on us and our consolidated subsidiaries and the securities we are offering. Statements in this prospectus concerning any document we filed as an exhibit to the registration statement or that we otherwise filed with the SEC are not intended to be comprehensive and are qualified by reference to these filings. You should review the complete document to evaluate these statements. You can obtain a copy of the registration statement from the SEC at the address listed above or from the SEC’s website.
INCORPORATION BY REFERENCE
The SEC allows us to incorporate by reference in this prospectus much of the information we file with the SEC, which means that we can disclose important information to you by referring you to those publicly available documents. The information that we incorporate by reference in this prospectus is considered to be part of this prospectus. Because we are incorporating by reference future filings with the SEC, this prospectus is continually updated and those future filings may modify or supersede some of the information included or incorporated in this prospectus. This means that you must look at all of the SEC filings that we incorporate by reference to determine if any of the statements in this prospectus or in any document previously incorporated by reference have been modified or superseded. This prospectus incorporates by reference the documents listed below (File No. 001-35969) and any future filings we make with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended, or the Exchange Act (in each case, other than those documents or the portions of those documents not deemed to be filed) until the offering of the securities under the registration statement is terminated or completed:
•
Annual Report on Form 10-K for the fiscal year ended December 31, 2019, including the information specifically incorporated by reference into the Annual Report on Form 10-K from our
definitive proxy statement for the 2020 Annual Meeting of Stockholders, filed on April 27, 2020;
•
•
Current Reports on Form 8-K filed on
August 24, 2018,
January 17, 2020 (solely with respect to Item 9.01 and Exhibits 99.3 and 99.4),
March 16, 2020 (excluding Item 7.01 and Exhibit 99.1),
19
April 30, 2020 (Film #20835722),
May 6, 2020 (excluding Item 7.01 and Exhibit 99.1),
June 4, 2020 and
June 10, 2020; and
•
A statement contained in a document incorporated by reference into this prospectus shall be deemed to be modified or superseded for purposes of this prospectus to the extent that a statement contained in this prospectus, any prospectus supplement or in any other subsequently filed document which is also incorporated in this prospectus modifies or replaces such statement. Any statements so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this prospectus.
You may request a copy of these filings, at no cost, by writing or telephoning us at the following address or phone number:
PTC Therapeutics, Inc.
100 Corporate Court
South Plainfield, New Jersey 07080
(908) 222-7000
100 Corporate Court
South Plainfield, New Jersey 07080
(908) 222-7000
20
PART II.
INFORMATION NOT REQUIRED IN PROSPECTUS
INFORMATION NOT REQUIRED IN PROSPECTUS
Item 14.
Other Expenses of Issuance and Distribution.
The following table sets forth the various expenses to be incurred in connection with the sale and distribution of the securities being registered hereby, all of which will be borne by the Registrant (except any underwriting discounts and commissions and expenses incurred by the selling stockholders for brokerage, accounting, tax or legal services or any other expenses incurred by the selling stockholders in disposing of the shares). All amounts shown are estimates except the SEC registration fee.
| |
SEC registration fee
|
| | | $ | 4,781.80 | | |
| |
Legal fees and expenses
|
| | | $ | 18,000 | | |
| |
Accounting fees and expenses
|
| | | $ | 46,000 | | |
| |
Miscellaneous expenses
|
| | | $ | 6,000 | | |
| |
Total expenses
|
| | | $ | 74,781.80 | | |
Item 15.
Indemnification of Directors and Officers.
Section 102 of the Delaware General Corporation Law permits a corporation to eliminate the personal liability of its directors or its stockholders for monetary damages for a breach of fiduciary duty as a director, except where the director breached his or her duty of loyalty, failed to act in good faith, engaged in intentional misconduct or knowingly violated a law, authorized the payment of a dividend or approved a stock repurchase in violation of Delaware corporate law or obtained an improper personal benefit. The Registrant’s certificate of incorporation provides that no director shall be personally liable to it or its stockholders for monetary damages for any breach of fiduciary duty as a director, notwithstanding any provision of law imposing such liability, except to the extent that the Delaware General Corporation Law prohibits the elimination or limitation of liability of directors for breaches of fiduciary duty.
Section 145 of the Delaware General Corporation Law provides that a corporation has the power to indemnify a director, officer, employee or agent of the corporation and certain other persons serving at the request of the corporation in related capacities against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlements actually and reasonably incurred by the person in connection with an action, suit or proceeding to which he or she is or is threatened to be made a party by reason of such position, if such person acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the corporation, and, in any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful, except that, in the case of actions brought by or in the right of the corporation, no indemnification shall be made with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or other adjudicating court determines that, despite the adjudication of liability but in view of all of the circumstances of the case, such person is fairly and reasonably entitled to indemnify for such expenses which the Court of Chancery or such other court shall deem proper.
The Registrant’s certificate of incorporation provides that it will indemnify each person who was or is a party or threatened to be made a party to any threatened, pending or completed action, suit or proceeding whether civil, criminal, administrative or investigative (other than an action by or in the right of us) by reason of the fact that he or she is or was, or has agreed to become, the Registrant’s director or officer, or is or was serving, or has agreed to serve, at the Registrant’s request as a director, officer, partner, employee or trustee of, or in a similar capacity with, another corporation, partnership, joint venture, trust or other enterprise (all such persons being referred to as an “Indemnitee”), or by reason of any action alleged to have been taken or omitted in such capacity, against all expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred in connection with such action, suit or proceeding and any appeal therefrom, if such Indemnitee acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, the Registrant’s best interests, and, with respect to any criminal action or proceeding, he or she had no reasonable cause to believe his or her conduct was unlawful.
II-1
The Registrant’s certificate of incorporation also provides that the Registrant will indemnify any Indemnitee who was or is a party to an action or suit by or in the right of the Registrant to procure a judgment in its favor by reason of the fact that the Indemnitee is or was, or has agreed to become, the Registrant’s director or officer, or is or was serving, or has agreed to serve, at the Registrant’s request as a director, officer, partner, employee or trustee or, or in a similar capacity with, another corporation, partnership, joint venture, trust or other enterprise, or by reason of any action alleged to have been taken or omitted in such capacity, against all expenses (including attorneys’ fees) and, to the extent permitted by law, amounts paid in settlement actually and reasonably incurred in connection with such action, suit or proceeding, and any appeal therefrom, if the Indemnitee acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, the Registrant’s best interests, except that no indemnification shall be made with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable to the Registrant, unless a court determines that, despite such adjudication but in view of all of the circumstances, he or she is entitled to indemnification of such expenses. Notwithstanding the foregoing, to the extent that any Indemnitee has been successful, on the merits or otherwise, he or she will be indemnified by the Registrant against all expenses (including attorneys’ fees) actually and reasonably incurred by him or her or on his or her behalf in connection therewith. If the Registrant does not assume the defense, expenses must be advanced to an Indemnitee under certain circumstances.
The Registrant has entered into indemnification agreements with its directors and executive officers. In general, these agreements provide that the Registrant will indemnify the director or executive officer to the fullest extent permitted by law for claims arising in his or her capacity as a director or officer of the Registrant or in connection with their service at the Registrant’s request for another corporation or entity. The indemnification agreements also provide for procedures that will apply in the event that a director or executive officer makes a claim for indemnification and establish certain presumptions that are favorable to the director or executive officer.
The Registrant maintains a general liability insurance policy which covers certain liabilities of its directors and officers arising out of claims based on acts or omissions in their capacities as directors or officers.
Item 16.
Exhibits.
†
Portions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K.
*
Filed herewith.
Item 17.
Undertakings.
The undersigned Registrant hereby undertakes:
II-2
(1)
To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:
(i)
to include any prospectus required by Section 10(a)(3) of the Securities Act of 1933, as amended (the “Securities Act”);
(ii)
to reflect in the prospectus any facts or events arising after the effective date of this registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in this registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Securities and Exchange Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20 percent change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement; and
(iii)
to include any material information with respect to the plan of distribution not previously disclosed in this registration statement or any material change to such information in this registration statement;
provided, however, that paragraphs (1)(i), (1)(ii) and (1)(iii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Securities and Exchange Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), that are incorporated by reference in this registration statement, or is contained in a form of prospectus filed pursuant to Rule 424(b) that is part of this registration statement.
(2)
That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
(3)
To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.
(4)
That, for the purpose of determining liability under the Securities Act to any purchaser:
(i)
each prospectus filed by the Registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the date the filed prospectus was deemed part of and included in the registration statement; and
(ii)
each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii) or (x) for the purpose of providing the information required by Section 10(a) of the Securities Act shall be deemed to be part of and included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. Provided, however , that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference in the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement
II-3
or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date.
(5)
That, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in this registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.
EXHIBIT INDEX
A list of exhibits filed herewith is contained in “Item 16. Exhibits” and is incorporated herein by reference.
II-4
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the Borough of South Plainfield, State of New Jersey, on this 19th day of June, 2020.
| | | | | PTC THERAPEUTICS, INC. | | |||
| | | | | By: | | |
/s/ STUART W. PELTZ, PH.D.
|
|
| | | | | | | |
Stuart W. Peltz, Ph.D.
Chief Executive Officer |
|
POWER OF ATTORNEY AND SIGNATURES
We, the undersigned officers and directors of PTC Therapeutics, Inc., hereby severally constitute and appoint Stuart W. Peltz, Emily Hill and Mark E. Boulding, and each of them singly, our true and lawful attorneys with full power to any of them, and to each of them singly, to sign for us and in our names in the capacities indicated below the Registration Statement on Form S-3 filed herewith and any and all amendments (including post-effective amendments) to said Registration Statement, and to file or cause to be filed the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, and generally to do all such things in our name and on our behalf in our capacities as officers and directors to enable PTC Therapeutics, Inc. to comply with the provisions of the Securities Act of 1933, as amended, and all requirements of the Securities and Exchange Commission, hereby ratifying and confirming all that said attorneys, and each of them, or their substitute or substitutes, shall do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.
| |
Signature
|
| |
Title
|
| |
Date
|
|
| |
/s/ STUART W. PELTZ, PH.D.
Stuart W. Peltz, Ph.D.
|
| | Chief Executive Officer and Director (Principal Executive Officer) | | |
June 19, 2020
|
|
| |
/s/ EMILY HILL
Emily Hill
|
| |
Chief Financial Officer
(Principal Financial Officer) |
| |
June 19, 2020
|
|
| |
/s/ CHRISTINE UTTER
Christine Utter
|
| |
Chief Accounting Officer
(Principal Accounting Officer) |
| |
June 19, 2020
|
|
| |
/s/ MICHAEL SCHMERTZLER
Michael Schmertzler
|
| | Chairman of the Board and Director | | |
June 19, 2020
|
|
| |
/s/ ALLAN JACOBSON, PH.D.
Allan Jacobson, Ph.D.
|
| | Director | | |
June 19, 2020
|
|
| |
/s/ STEPHANIE S. OKEY, M.S.
Stephanie S. Okey, M.S.
|
| | Director | | |
June 19, 2020
|
|
| |
/s/ EMMA REEVE
Emma Reeve
|
| | Director | | |
June 19, 2020
|
|
| |
Signature
|
| |
Title
|
| |
Date
|
|
| |
/s/ DAVID P. SOUTHWELL
David P. Southwell
|
| | Director | | |
June 19, 2020
|
|
| |
/s/ GLENN D. STEELE, JR., M.D., PH.D.
Glenn D. Steele, Jr., M.D., Ph.D.
|
| | Director | | |
June 19, 2020
|
|
| |
/s/ DAWN SVORONOS
Dawn Svoronos
|
| | Director | | |
June 19, 2020
|
|
| |
/s/ JEROME B. ZELDIS, M.D., PH.D.
Jerome B. Zeldis, M.D., Ph.D.
|
| | Director | | |
June 19, 2020
|
|
Exhibit 5.1
![[MISSING IMAGE: lg_morganlewis-bw.jpg]](/stocks/ptct/documents/23f95c02-8c01-4524-aaf6-4bc6261b950c/asset/lg_morganlewis-bw.jpg){kind=small}
June 19, 2020
PTC Therapeutics, Inc.
100 Corporate Court
South Plainfield, New Jersey 07080
100 Corporate Court
South Plainfield, New Jersey 07080
Re:
PTC Therapeutics, Inc. Registration Statement on Form S-3
Ladies and Gentlemen:
We have acted as counsel to PTC Therapeutics, Inc., a Delaware corporation (the “Company”), in connection with the preparation of a Registration Statement on Form S-3 (the “Registration Statement”) for filing with the Securities and Exchange Commission (the “SEC”) pursuant to the Securities Act of 1933, as amended (the “Act”), for the registration by the Company of 760,365 shares (the “Shares”) of common stock, par value $0.001 per share, of the Company (the “Common Stock”), which are held by former securityholders (the “Selling Stockholders”) of Censa Pharmaceuticals Inc., a Delaware corporation (“Censa”), pursuant to the registration rights the Company provided to the Selling Stockholders in Section 5.11 of the Agreement and Plan of Merger (the “Merger Agreement”), dated May 5, 2020, by and among the Company, Hydro Merger Sub, Inc., a Delaware corporation, Censa and, solely in its capacity as the Securityholders’ Representative, Shareholder Representative Services LLC, a Colorado limited liability company.
We have examined the Registration Statement, the Merger Agreement, the Restated Certificate of Incorporation of the Company, the Amended and Restated Bylaws of the Company, and such certificates, records, statutes and other documents as we have deemed relevant in rendering this opinion. As to matters of fact, we have relied on representations of officers of the Company. In our examination, we have assumed the genuineness of documents submitted to us as originals and the genuineness of, and conformity with, the original of all documents submitted to us as copies thereof.
We assume that the appropriate action will be taken, prior to the offer and sale of the Shares by the Selling Stockholders, to register and qualify the Shares for sale under all appropriate state securities or “blue sky” laws.
Based upon the foregoing, we are of the opinion that the Shares have been duly authorized by the Company and are validly issued, fully paid and non-assessable.
It is understood that this opinion is to be used solely in connection with the offer and sale of the Shares while the Registration Statement is in effect.
The opinion set forth above is limited to the laws of the Delaware General Corporation Law.
We hereby consent to the use of this opinion as Exhibit 5.1 to the Registration Statement and to the reference to us under the caption “Legal Matters” in the prospectus included in the Registration Statement. In giving such consent, we do not thereby admit that we are acting within the category of persons whose consent is required under Section 7 of the Act or the rules or regulations of the SEC thereunder.
Very truly yours,
/s/ Morgan, Lewis & Bockius LLP
![[MISSING IMAGE: lh_morganlewis-bw.jpg]](/stocks/ptct/documents/23f95c02-8c01-4524-aaf6-4bc6261b950c/asset/lh_morganlewis-bw.jpg)
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the reference to our firm under the caption “Experts” in the Registration Statement (Form S-3) and related Prospectus of PTC Therapeutics, Inc. for the registration of common stock and to the incorporation by reference therein of our reports dated March 2, 2020, with respect to the consolidated financial statements of PTC Therapeutics, Inc. and the effectiveness of internal control over financial reporting of PTC Therapeutics, Inc. included in its Annual Report (Form 10-K) for the year ended December 31, 2019, filed with the Securities and Exchange Commission.
/s/ Ernst & Young LLP
Iselin, New Jersey
June 19, 2020
June 19, 2020
Exhibit 23.2
Consent of Independent Certified Public Accounting Firm
PTC Therapeutics, Inc.
South Plainfield, New Jersey
South Plainfield, New Jersey
We hereby consent to the incorporation by reference in the Prospectus constituting a part of this Registration Statement of PTC Therapeutics, Inc. of our report dated August 21, 2018, relating to the consolidated financial statements of Agilis Biotherapeutics, Inc. (“the Company”) as of and for the years ended December 31, 2017 and 2016 appearing in PTC Therapeutics, Inc.’s Form 8-K filed on August 24, 2018. Our report contains an explanatory paragraph regarding the Company’s ability to continue as a going concern.
We also consent to the reference to us under the caption “Experts” in the Prospectus.
/s/ BDO USA, LLP
Boston, Massachusetts
Boston, Massachusetts
June 19, 2020